The usefulness of RFA for the pulmonary metastasis associated with kidney cancer

The usefulness of RFA for the pulmonary metastasis associated with kidney cancer - RFA-Lung-RCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004079

Enrollment

Registered

2010-08-20

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the cases with pulmonary metastasis associated with kidney cancer

Interventions

the treatment with RFA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diagnosis of kidney cancer 2) pulmonary metastasis diagnosed with radiological examination 3) pulmonary sites and size (less than 3 and less than 3cm) 4) resistance against immunotherapy 5) WHO 0 or 1 6) Received informed and consensus to entry this study

Exclusion criteria

Exclusion criteria: 1) General dysfunction including bone marrow function, hepatic function, renal function, heart function 2) Active other organ originated cancer 3) The physician deny to entry

Design outcomes

Primary

Measure	Time frame
Over all survival	—

Secondary

Measure	Time frame
Local recurrence Cause specific survival Progression free survival QOL	—

Countries

Japan

Contacts

Public ContactNorihito Soga

Mie university urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026